Suppr超能文献

米非司酮预处理联合米索前列醇用于有剖宫产史的中孕期药物流产。

Mifepristone priming and subsequent misoprostol for second trimester medical abortion in women with previous caesarean delivery.

机构信息

Maternal Fetal Medicine, Division of Obstetrics and Gynaecology, The University of Western Australia, Perth, Western Australia, Australia.

Biostatistics and Research Design Unit, Division of Obstetrics and Gynaecology, The University of Western Australia, Perth, Western Australia, Australia.

出版信息

Aust N Z J Obstet Gynaecol. 2023 Jun;63(3):301-307. doi: 10.1111/ajo.13653. Epub 2023 Feb 15.

Abstract

AIMS

To assess clinical outcomes and complications in women with ≥1 prior caesarean delivery (CS) during mid-pregnancy medical abortion with misoprostol following mifepristone priming.

MATERIALS AND METHODS

Retrospective analysis of abortions at 13-28 weeks gestation using sequential mifepristone and misoprostol at a single centre from 1/2008-12/2018. Procedural outcomes were compared between cases with no prior CS, one prior and ≥2 prior CS.

RESULTS

There were 1399 consecutive women who underwent a medical abortion, with 304 (21.7%) having ≥1 prior lower segment CS (241 one, 49 two, 12 three, one four) and one a prior classical CS. Median gestation was 19 weeks (interquartile range (IQR) 17-21) among nulliparas, multiparas with no prior CS and multiparas with prior CS, P = 0.505. Compared with nulliparas (median procedural duration 10.8 h, IQR 7.5-16.5; adjusted hazards ratio (aHR) = 1.20 95%CI 1.04-1.40, P = 0.015), multiparas with prior CS had a shorter procedural duration (9.5 h, IQR 6.5-13.5) while multiparas with no CS had the shortest duration (7.0 h, IQR 5.0-9.8; aHR = 2.28 95%CI 2.01-2.58, P < 0.001). Complications were more frequent with prior CS: estimated blood loss (medians: 100 cc no CS vs 150 cc ≥1 CS, P = 0.002), blood loss >1000 cc (3.6% no CS vs 7.2% ≥1 CS; odds ratio (OR) = 2.11 95%CI 1.23-3.62, P = 0.007) and placental retention (17.3% no CS vs 25.3% ≥1 CS; adjusted OR = 1.44 95%CI 1.05-1.99, P = 0.024). Uterine rupture occurred in 4/304 women with ≥1 prior CS (1.3%).

CONCLUSIONS

Mifepristone-misoprostol abortion in women with prior CS is generally safe but associated with an increased risk of procedural complications. Lowering of the misoprostol dosage with prior CS may reduce uterine rupture, although this hypothesis requires ongoing research.

摘要

目的

评估米非司酮联合米索前列醇在有剖宫产史的孕妇中进行中期妊娠药物流产的临床结局和并发症。

材料和方法

回顾性分析了 2008 年 1 月至 2018 年 12 月期间在一家中心进行的 13-28 周妊娠的药物流产,使用序贯米非司酮和米索前列醇。将无剖宫产史、有一次剖宫产史和有≥2 次剖宫产史的病例进行比较。

结果

共有 1399 例连续接受药物流产的妇女,其中 304 例(21.7%)有≥1 次下腹部剖宫产史(241 例一次,49 例两次,12 例三次,1 例四次),1 例为经典剖宫产史。初产妇、无剖宫产史的多产妇和有剖宫产史的多产妇的中位妊娠时间为 19 周(四分位间距(IQR)17-21),P=0.505。与初产妇相比(手术时间中位数 10.8 小时,IQR 7.5-16.5;调整后的危害比(aHR)1.20,95%CI 1.04-1.40,P=0.015),有剖宫产史的多产妇手术时间较短(9.5 小时,IQR 6.5-13.5),而无剖宫产史的多产妇手术时间最短(7.0 小时,IQR 5.0-9.8;aHR 2.28,95%CI 2.01-2.58,P<0.001)。有剖宫产史的孕妇并发症更常见:估计出血量(中位数:无 CS 100cc vs. ≥1 CS 150cc,P=0.002),出血量>1000cc(无 CS 3.6% vs. ≥1 CS 7.2%;比值比(OR)2.11,95%CI 1.23-3.62,P=0.007)和胎盘残留(无 CS 17.3% vs. ≥1 CS 25.3%;调整 OR 1.44,95%CI 1.05-1.99,P=0.024)。≥1 次剖宫产的孕妇中发生 4 例子宫破裂(1.3%)。

结论

米非司酮联合米索前列醇终止有剖宫产史的孕妇妊娠一般是安全的,但与手术并发症的风险增加有关。对于有剖宫产史的孕妇,降低米索前列醇的剂量可能会降低子宫破裂的风险,但这一假说需要进一步的研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验